Andros Pharmaceuticals Co (ROCO:6917) Other Current Receivables: NT$0.58 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6917 Andros Pharmaceuticals Co Ltd ROCO:6917
40 GF Score
Price NT$33.25
GF Value NT$166.23
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Andros Pharmaceuticals Co Other Current Receivables?

Andros Pharmaceuticals Co ROCO:6917 -0.45% 40 Other Current Receivables is NT$0.58 Mil as of Dec. 2025. GuruFocus rates ROCO:6917 with a GF Score™ of 40/100 and a GF Value™ of NT$166.23 (Possible Value Trap). The stock has 4 warning signs investors should review.

Andros Pharmaceuticals Co's Other Current Receivables for the quarter that ended in Dec. 2025 was NT$0.58 Mil.

Andros Pharmaceuticals Co's quarterly Other Current Receivables declined from Dec. 2024 (NT$0.47 Mil) to Jun. 2025 (NT$0.41 Mil) but then increased from Jun. 2025 (NT$0.41 Mil) to Dec. 2025 (NT$0.58 Mil).

Andros Pharmaceuticals Co's annual Other Current Receivables increased from Dec. 2023 (NT$0.41 Mil) to Dec. 2024 (NT$0.47 Mil) and increased from Dec. 2024 (NT$0.47 Mil) to Dec. 2025 (NT$0.58 Mil).

Andros Pharmaceuticals Co Other Current Receivables Related Terms

Andros Pharmaceuticals Co Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Andros Pharmaceuticals Co's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Andros Pharmaceuticals Co Other Current Receivables Chart

Andros Pharmaceuticals Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial 4.37 0.21 0.41 0.47 0.58

Andros Pharmaceuticals Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.41 0.32 0.47 0.41 0.58
ROCO:6917
40GF Score
Andros Pharmaceuticals Co Ltd ROCO:6917
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Andros Pharmaceuticals Co Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of NT$0.58 Mil mean?
Andros Pharmaceuticals Co (ROCO:6917) has a Other Current Receivables of NT$0.58 Mil as of Dec. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Andros Pharmaceuticals Co and its competitors.
Is Andros Pharmaceuticals Co's Other Current Receivables too high?
Andros Pharmaceuticals Co's current Other Current Receivables is NT$0.58 Mil. Overall, Andros Pharmaceuticals Co has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Andros Pharmaceuticals Co's Other Current Receivables compare to VRTX and REGN?
Andros Pharmaceuticals Co's Other Current Receivables of NT$0.58 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Andros Pharmaceuticals Co and its competitors. Andros Pharmaceuticals Co's current Other Current Receivables is NT$0.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Andros Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Andros Pharmaceuticals Co (ROCO:6917) is currently considered Possible Value Trap. The stock's GF Value™ is NT$166.23, compared to a current price of NT$33.25 — trading 80% below its estimated fair value. The current Other Current Receivables is NT$0.58 Mil. Andros Pharmaceuticals Co's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Andros Pharmaceuticals Co (ROCO:6917), the current Other Current Receivables is NT$0.58 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Andros Pharmaceuticals Co (ROCO:6917) Overvalued in 2026?

Based on GuruFocus' analysis, Andros Pharmaceuticals Co stock appears to be undervalued. The current stock price of NT$33.25 is trading 80% below its estimated GF Value™ of NT$166.23. GuruFocus considers Andros Pharmaceuticals Co to be Possible Value Trap.

Key valuation signals for ROCO:6917:

  • Other Current Receivables: NT$0.58 Mil
  • GF Value™: NT$166.23 vs. price of NT$33.25 (80% below fair value)
  • GF Score™: 40/100 with 4 warning signs

No single metric tells the full story. See the ROCO:6917 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Andros Pharmaceuticals Co Business Description

Address No. 22, Sec. 2, Shengyi Road, 6th Floor, Building D, Biotech Building, Hsinchu Biomedical Science Park, Hsinchu County, Zhubei City, TWN, 30261
Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).
40GF Score

Get the complete analysis for ROCO:6917

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$33.25
Price
NT$166.23
GF Value